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Dyspnea is defined by the American Thoracic Society as 
a subjective experience of breathing discomfort that 
consists of qualitatively distinct sensations varying in 
intensity [1]. A peak incidence of the symptoms of 
breathlessness is between 55 and 69 years of age [2]. In 85 
percent the causes of anhelation are asthma, chronic 
obstructive pulmonary disease (COPD), pneumonia, 
interstitial lung disease, congestive heart failure, cardiac 
ischemia or psychogenic conditions [3, 4]. If the symptom 
lasts for longer than one month, they are defined as a 
chronic dyspnea [5]. Chronic dyspnea usually appears due 
to one of the following causes: mostly bronchial asthma, 
COPD, congestive heart failure, interstitial lung disease, 
pneumonia, or mental disorders like anxiety disorders, 
panic disorders or somatization disorders [6, 7]. 
 
Asthma as one of the most common causes of 
anhelation, affects 24 million people worldwide [8]. The 
chronic inflammation of the respiratory tract is associated 
with airway hyper responsiveness leading to recurrent 
episodes of breathlessness, wheezing, chest tightness, and 
coughing [9]. Another important cause of dyspnea is COPD. 
Around 2% of the whole population – 4.5% of all people 
aged over 40 – suffer from diagnosed COPD [10]. This 
disease is characterized by persistent respiratory 
symptoms and airflow limitation due to airway and/or 
alveolar abnormalities. Next to breathlessness, the most 





Complementary and Alternative Medicine: Open Access 





Background: Asthma and chronic obstructive pulmonary disease (COPD) are the leading causes for dyspnea. Guidelines 
suggest many therapeutic options for the treatment of these respiratory symptoms with Western medicine. However, there is 
still a lack in therapy control, and the side effects of the used drugs are also not neglect able. Traditional Chinese Medicine might 
offer an individual, safe and effective complementary therapy option.  
 
Case presentation: A 60-year-old Caucasian man suffering from asthma and COPD had a recourse to our clinic. His chronic 
exertional breathlessness was diagnosed as having no other origin but his primary diseases. The use of Western medicine left 
his symptoms unchanged. After three weeks of therapy with Traditional Chinese Medicine containing a combination of herbal 
extracts and acupuncture, his dyspnea disappeared, enabling the patient to cope with his workload. Altogether three months 
later his pulmonary function test has notably improved compared to the previous one (Maximal vital capacity 102% vs. 51%, 
Forced expiratory volume in 1 second 106% vs. 52%, Total lung capacity 107% vs. 69%, respectively). 
 
Conclusions: Chinese medicine appears to be a good integrative method, especially in therapy resistant anhelation or poorly 
controlled respiratory diseases. A high number of patients suffering from such conditions might be affected, to whom 
complementary medicine could be helpful.  
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production, although the symptoms are commonly under-
reported by patients [11].  
 
Many categories of drugs were developed to treat 
asthma and COPD. These are bronchodilators (β-adrenergic 
agonists, anticholinergics and methylxanthines) and anti-
inflammatory agents (corticosteroids, antileukotrienes and 
mast cell stabilizers) [12] against asthma. Short-and long-
acting bronchodilators are the mainstays of therapy for 
COPD, inhaled corticosteroids are reserved for patients 
with refractory or severe disease [13]. 
 
Current synthetic drugs used in the pharmacotherapy 
are unable to act during all stages and towards all targets of 
asthma [14], and there is no curative therapy available. 
Pharmacologic therapy for COPD reduces symptoms and 
the frequency, as well as the severity of exacerbations. It 
improves exercise tolerance and health status of the 
patients [11], but there is no existing medication that could 
modify the long-term decline in lung function [15-18]. 
Moreover, side effects from chronic use of current drugs are 
an issue of concern [19, 20]. 
 
Hence, it is not surprising, that at least one-fifth of 
patients with respiratory disorders, such as asthma and 
COPD are longing for complementary and alternative 
treatments, including acupuncture, herbal medicine, and 
lifestyle advice [21, 22]. Recently, multiple clinical studies 
showed that Traditional Chinese Medicine (TCM) is safe 
and effective for the treatment of asthma [23, 24]. As 
reviewed by Li et al., several clinical studies showed an 
improvement in lung functions, were all addressed safety 
and well tolerated. Although demonstrating significant 
improvement in asthmatic symptoms, all studies have 
limitations such as short follow-up periods or small sample 
size in the placebo arm [24]. On the other hand, there is 
accumulating evidence proving that TCM -including 
internal and external therapies – might have potential 
advantages in COPD as well [25-33]. Thus, the frequency of 
acute exacerbation was found to be reduced, leading to an 
improvement of life quality [34]. However, to our 
knowledge there are so far no reports available providing 





Our clinic received a 60-year-old male patient suffering 
from asthma and COPD, with chronic dyspnea lasting for 
the past eight months. Symptoms occurred after even as 
little as 1-2 minutes walking or speaking. In the medical 
history hypertension, benign prostatic hyperplasia, 
hypercholesterinaemia, low-grade aortic insufficiency, 
hepatic steatosis, pollenosis and penicillin allergy were 
mentioned. The patient was operated for right-side 
inguinal hernia, left ankle ligament rupture and left medial 
meniscus rupture. The patient’s medication consisted of 
amlodipin (2x5mg), pantoprazol (2x40 mg), 
beclometason/ formoterol spray (100 µg/6 µg 2-0-2), 
salbutamol (1,25 mg/2,5 ml 1-0-1), ebastin (20 mg 1-0-1), 




The non-smoking patient suffered from recurrent 
respiratory tract infection with anhelation for the past 30 
years. Returning to Germany from the Caribbean in 
February 2016, his new dyspnea was provoked even after 
minimal load. No infections were detected. The 
intermittent coughing was accompanied by no, or only little 
sputum of white color. Hemoptysis, fever, night sweating or 
weight loss were not present. The thorax X-ray from March 
2016 did not show any infiltrate, only some light 
chronically increased bronchovascular markings due to the 
primary asthmatic disease were present. The pulmonary 
function test showed a moderately obstructive and 
restrictive ventilatory defect. In the computed tomography 
of May 2016, accented paratracheal lymph nodes on the 
right side and around the right hilus with its maximal 
intensity next to the right primary bronchus (maximal 
height: 12 mm) were visible. An examination by a 
cardiologist in an outpatient clinic failed to show any 
cardiologic origin of the breathlessness. The ENT specialist 
diagnosed gastroesophageal reflux disease and 
recommended to continue the PPI therapy. The 
ergospirometry in May 2016 failed to show any restriction 
of the lung function, but showed an increased basal heart 
rate; the cardio workout was about 160/min (140 Watt). 
The renin, aldosterone and aldosterone/renin ratio and the 
urine catecholamines were in normal range. 
 
The findings of the physical examinations were normal 
except for slightly reduced respiratory sounds – during 
speaking a light dyspnea was obvious. Physical parameters 
were in normal range: the ranges of systolic and diastolic 
blood pressures were 120-150/70-90 mmHg, the heart rate 
between 60-82/min, and the oxygen saturation between 
94-97%. Laboratory findings showed a slightly increased 
serum glutamic-pyruvic transaminase level (GPT=86.9 
U/l), while the other parameters were in the normal range. 
In the psychological conversations there were no signs of 
depression, schizophrenia, anxiety-, panic-, mental- or 
somatization disorders. 
  
When he was observed in our clinic, the patient’s tongue 
was pale and fissured with a white tongue coating. The 
pulse was deep, chordal; the kidney (chi) pulse was weak. 
The Chinese diagnosis was ‘Spleen-Lung-Qi-deficiency’. 
The therapy consisted of Chinese herbal tea two times per 
day, acupuncture three times per week and a daily qigong 
therapy. The first prescription to be ingested for seven days 
consisted of: Astragali radix (Huangqi) 6 g Codonopsis 
pilosulae radix (Dangshen) 6 g, Atractylodis macrocephalae 
rhizoma (Baizhu) 6 g, Poria (Fulingkuai) 6 g, Polygonati 
rhizoma (Huangjing) 6 g, Lycii fructus (Gouqizi) 6 g, 
Ophiopogonis radix (Maidong) 6 g, Schisandrae fructus 
(Wuweizi) 3 g.  
 
After one week the prescription was changed based on 
the purple tongue with thin greasy and yellow tongue 
coating adding ‘blood stasis’ and ‘phlegm’ to the Chinese 
diagnosis. Additional night sweating appeared. The second 
recipe consisted of: Poria (Fulingkuai) 6 g, Schisandrae 
fructus (Wuweizi) 3 g, Ephedrae herba (Mahuang) 3 g, 
Persicae semen (Taoren) 6 g, Armeniacae amarum semen 
(Kuxingren) 6 g, Luffae fructus retinervus (Sigualuo) 6 g,  
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Magnoliae officinalis cortex (Houpo) 6 g, Curcumae radix 
(Yujin) 6 g, Mori radicis cortex (Sangbaipi) 6 g, Bambusae 
caulis in taeniam (Zhuru) 6 g, Phragmitis rhizoma (Lugen) 
6 g, Imperatae rhizoma (Baimaogen) 6 g, Lycii radicis 
cortex (Digupi) 6 g, Rhizoma sparganii tuber (Sanleng) 6 g.  
 
The following points were targeted with acupuncture: 
Conception Vessel 4, 12, 17; Spleen 6, 15; Large intestine 4, 
11; Stomach 37. 
 
Ingestion of this second prescription for 2 days reduced 
the anhelation. 9 days later the patient could walk without 
limits (10 km daily were reported). The salbutamol 
medication could be stopped on the 14thday of the therapy 
and five days later the beclometason/formoterol doses 
could be halved. On the 22nd day of the therapy the GPT 
level was reduced to 58.3 U/l.  
 
After four complete weeks of therapy in the clinic, the 
patient was discharged in a very good condition without 
any signs of dyspnea and even with reduced respiratory 
medication. Treatment with the applied Chinese herbs was 
continued for two months after the discharge with a 
reduced dose of only 3 g each. The difference between the 
two lung function tests before and after Chinese medicine 
treatment is shown in Table 1. In November 2016 the 
patient visited or outpatient department without any 
symptoms of breathlessness; further therapy was found not 




In our case report a patient with treatment-resistant 
asthma and COPD was demonstrated, for whom excellent 
results could be achieved by a combination therapy of 
herbal extracts and acupuncture.  
 
According to TCM, dyspnea mainly occurs due to the 
energetic problems of functional circles like lung, spleen 
and kidney. The aim of the therapy is to restore the function 
of these functional circles, enhancing the circulation of Qi. 
To that aim TCM uses herbs and acupuncture asits main 
two therapy methods. 
 
The use of herbal medicine is increasing dramatically in 
the last decades worldwide [14, 35-37]. Thus, more than 
400 medical plant species are known with applications in 
traditionally and ethanopharmacologically to treat the 
symptoms of asthmatic disorders [12]. 
 
Chinese herbs form one of the most important and 
effective pillars of TCM, with reports on physiological 
effects in several studies. They do not only enable the 
improvement of asthmatic symptoms for example through 
direct spasmolytic effects, inhibiting the airway hyper-
responsiveness and blocking the acetylcholine-induced 
tracheal ring constriction [38-41], but also impact the 
regulation of the immune system, inhibiting the 
inflammatory cell infiltration of eosinophils, neutrophils, 
lymphocytes and macrophages into lung tissue or into the 
bronchoalveolar lavage fluids [42-44]. Furthermore, some  
Chinese herbs inhibit the production of Immunoglobulin E 
and the expression of inflammatory cytokines (such as  
 
 
TNF-alfa, IL-1β, IL-6, and macrophage-inflammatory 
peptide-2 by attenuating the activation of nuclear factor-
kappa B) [45-49]. Herba ephedrae is the most commonly 
used Chinese herb to treat dyspnea. Interestingly, of the 
most frequently used Chinese herbs treating respiratory 
diseases, like Radix glycyrrhizae, Semen armeniacae 
amarum, Fructus schisandrae chinese, Herba ephedrae and 
Radix ginseng (including in the prescriptions 47.2%, 
36.7%, 21.2%, 20.6%, 19.4%, respectively), only Herba 
ephedrae was used in our prescription [50]. Said herb can 
improve the flow of Lung Qi in order to relieve cough and 
anhelation, and has been used in China for thousands of 
years. It was reported to have anti-inflammatory, anti-
tussive and anti-asthmatic effects [27]. Ephedrine was 
identified as its active component; D-pseudephedrine has 
anti-inflammatory action which could reduce 
vasopermeability. Additionally, several flavonoids isolated 
from Herba ephedrae were reported to exhibit radical 
scavenging activity [50, 51]. 
 
Mostly applied in combination with the use of Chinese 
herbs, the second important and effective pillar of TCM is 
acupuncture. Animal experiments showed improvements 
in the pulmonary function and lung pathology in COPD. The 
COPD rats, treated with the so-called Bufei Yishen granule 
together with acupoint-sticking showed better outcomes 
than acupoint-sticking or treatment with aminophylline 
alone [52]. In another rat model, Li et al. showed that 
acupuncture treatment appeared to reduce the COPD-
induced inflammatory response by decreasing cell 
inflammation. Furthermore, it reduced the production of 
TNF-α and IL-8 in the bronchoalveolar lavage fluid in 
smoke-induced COPD by modulating Histone deacetylase 2. 
The pulmonary function test showed that reductions in 
peak expiratory flow, inspiratory capacity and minute 
volume in COPD were normalized after acupuncture 
treatment [53]. In human studies, COPD patients receiving 
traditional acupuncture experienced improvement in 
dyspnea on exertion and 6-min walking distance, indicating 
better exercise tolerance. In patients receiving standard 
medication, acupuncture was superior to placebo in 
improving breathlessness [54, 55]. Geng et al. suggested 
that acupuncture may reduce lung injury associated with 
COPD, possibly through downregulation of inflammatory 
cytokines. Anti-inflammatory and antioxidant effects have 
been implicated in the clinical benefit of electro-
acupuncture [56]. 
 
In conclusion, in our case Chinese medicine was an 
effective complementary way to treat chronic dyspnea 
based on asthma and COPD. The improvement of the 
symptoms seemed to be long-lasting and was confirmed 
objectively with spirometry test.  
 
This case suggests that additive complementary 
medicine could improve the condition of patients suffering 
from uncontrolled respiratory diseases. Such a 
complementary treatment can be a promising strategy for 
a high number of patients, especially for those, for whom 
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